Celldex Therapeutics (NASDAQ:CLDX) Price Target Raised to $46.00 at Morgan Stanley

Celldex Therapeutics (NASDAQ:CLDX) had its price target upped by Morgan Stanley from $40.00 to $46.00 in a research note published on Friday,Benzinga reports. They currently have an overweight rating on the biopharmaceutical company’s stock.

CLDX has been the topic of several other reports. UBS Group increased their target price on shares of Celldex Therapeutics from $38.00 to $45.00 and gave the stock a “buy” rating in a research note on Wednesday, June 10th. Wells Fargo & Company boosted their price target on shares of Celldex Therapeutics from $48.00 to $72.00 and gave the company an “overweight” rating in a research report on Wednesday, July 29th. Barclays upped their price target on shares of Celldex Therapeutics from $48.00 to $53.00 and gave the stock an “overweight” rating in a report on Friday. Canaccord Genuity Group lowered their price objective on Celldex Therapeutics from $62.00 to $60.00 and set a “buy” rating on the stock in a research report on Wednesday, July 22nd. Finally, HC Wainwright reissued a “buy” rating and set a $42.00 price objective on shares of Celldex Therapeutics in a research note on Monday, June 15th. One research analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $55.46.

Celldex Therapeutics Stock Up 0.4%

Shares of CLDX opened at $41.71 on Friday. Celldex Therapeutics has a twelve month low of $19.72 and a twelve month high of $42.92. The stock has a market cap of $3.27 billion, a PE ratio of -9.59 and a beta of 0.87. The business’s 50-day moving average price is $35.19 and its 200-day moving average price is $31.54.

Celldex Therapeutics (NASDAQ:CLDX) last released its quarterly earnings data on Thursday, August 6th. The biopharmaceutical company reported ($0.94) EPS for the quarter, beating analysts’ consensus estimates of ($1.06) by $0.12. The firm had revenue of $0.02 million during the quarter, compared to the consensus estimate of $0.73 million. Analysts expect that Celldex Therapeutics will post -4.36 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Celldex Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of CLDX. Wilmington Savings Fund Society FSB purchased a new stake in shares of Celldex Therapeutics during the 3rd quarter valued at $42,000. Russell Investments Group Ltd. increased its stake in Celldex Therapeutics by 27.6% in the second quarter. Russell Investments Group Ltd. now owns 2,315 shares of the biopharmaceutical company’s stock valued at $47,000 after acquiring an additional 501 shares during the last quarter. Quantbot Technologies LP purchased a new stake in Celldex Therapeutics during the third quarter valued at about $63,000. Kestra Advisory Services LLC purchased a new stake in Celldex Therapeutics during the fourth quarter valued at about $98,000. Finally, Headlands Technologies LLC bought a new stake in Celldex Therapeutics during the second quarter worth about $125,000.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted immunotherapies for cancer and other serious diseases. The company’s research platforms leverage novel antibody and vaccine technologies designed to engage the patient’s immune system, with a particular emphasis on oncology and neurologic indications. Celldex’s pipeline includes both monoclonal antibodies and biologic agents that seek to modulate immune responses or deliver targeted cytotoxic activity.

Among Celldex’s lead product candidates is glembatumumab vedotin, an antibody–drug conjugate directed against the glycoprotein NMB (gpNMB) for the treatment of certain breast and skin cancers.